검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 111In Zevalin (111In Zevalin) Spectrum Pharmaceuticals, Inc·Multiple Myeloma and Plasma Cell N… ORR 67.7%·t½ 2.8 h |
|---|---|
Overview Program | 111In Zevalin |
Overview Company | Spectrum Pharmaceuticals, Inc |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma and Plasma Cell Neoplas |
Overview Indication | Multiple Myeloma and Plasma Cell Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Half-life | 2.8 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.. A high-affinity IgG1 kappa murine monoclonal anti-CD20 antibody (IDEC-2B8) was developed for radioimmunotherapy of non-Hodgkin's B-cell lymphoma. A stable immunoconjugate (Zevalintrade mark) was prepared by reacting IDEC-2B8 with a derivative of diethylenetriaminepentaacetic acid, designat… |
Clinical Primary efficacy | ORR 67.7% |
Clinical ORR | 3.3% |
Clinical PFS | 0.62 |
Clinical Result source | ClinicalTrials.gov NCT00493467 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 6월 1일 (43일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 111In Zevalin (111In Zevalin) Spectrum Pharmaceuticals, Inc·Multiple Myeloma and Plasma Cell N… ORR 67.7%·t½ 2.8 h |
|---|---|
Overview Program | 111In Zevalin |
Overview Company | Spectrum Pharmaceuticals, Inc |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma and Plasma Cell Neoplas |
Overview Indication | Multiple Myeloma and Plasma Cell Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Half-life | 2.8 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.. A high-affinity IgG1 kappa murine monoclonal anti-CD20 antibody (IDEC-2B8) was developed for radioimmunotherapy of non-Hodgkin's B-cell lymphoma. A stable immunoconjugate (Zevalintrade mark) was prepared by reacting IDEC-2B8 with a derivative of diethylenetriaminepentaacetic acid, designat… |
Clinical Primary efficacy | ORR 67.7% |
Clinical ORR | 3.3% |
Clinical PFS | 0.62 |
Clinical Result source | ClinicalTrials.gov NCT00493467 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 6월 1일 (43일 전 · 갱신 권장) |
추천 비교
추천 비교